A detailed history of Twin Capital Management Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Twin Capital Management Inc holds 29,788 shares of GILD stock, worth $2.69 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
29,788
Previous 30,255 1.54%
Holding current value
$2.69 Million
Previous $2.08 Million 20.29%
% of portfolio
0.29%
Previous 0.25%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$66.59 - $83.99 $31,097 - $39,223
-467 Reduced 1.54%
29,788 $2.5 Million
Q2 2024

Aug 13, 2024

BUY
$63.15 - $72.88 $46,352 - $53,493
734 Added 2.49%
30,255 $2.08 Million
Q1 2024

May 13, 2024

SELL
$71.58 - $87.29 $157,762 - $192,387
-2,204 Reduced 6.95%
29,521 $2.16 Million
Q4 2023

Jan 31, 2024

BUY
$73.27 - $83.09 $446,434 - $506,267
6,093 Added 23.77%
31,725 $2.57 Million
Q3 2023

Nov 13, 2023

SELL
$73.94 - $80.67 $102,480 - $111,808
-1,386 Reduced 5.13%
25,632 $1.92 Million
Q2 2023

Aug 07, 2023

SELL
$76.01 - $86.7 $85,359 - $97,364
-1,123 Reduced 3.99%
27,018 $2.08 Million
Q1 2023

May 08, 2023

BUY
$77.31 - $88.08 $2.18 Million - $2.48 Million
28,141 New
28,141 $2.33 Million
Q1 2022

May 06, 2022

SELL
$57.92 - $72.58 $578,041 - $724,348
-9,980 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$64.88 - $73.64 $47,362 - $53,757
-730 Reduced 6.82%
9,980 $725,000
Q3 2021

Oct 29, 2021

BUY
$67.69 - $73.03 $10,762 - $11,611
159 Added 1.51%
10,710 $748,000
Q2 2021

Aug 09, 2021

SELL
$63.47 - $69.35 $12,630 - $13,800
-199 Reduced 1.85%
10,551 $727,000
Q1 2021

May 06, 2021

SELL
$60.0 - $68.46 $66,600 - $75,990
-1,110 Reduced 9.36%
10,750 $695,000
Q4 2020

Feb 11, 2021

SELL
$56.65 - $64.55 $48,095 - $54,802
-849 Reduced 6.68%
11,860 $691,000
Q3 2020

Nov 05, 2020

SELL
$62.1 - $78.08 $12,544 - $15,772
-202 Reduced 1.56%
12,709 $803,000
Q2 2020

Aug 04, 2020

SELL
$72.34 - $84.0 $12,514 - $14,532
-173 Reduced 1.32%
12,911 $993,000
Q1 2020

Apr 29, 2020

BUY
$62.63 - $80.22 $278,703 - $356,979
4,450 Added 51.54%
13,084 $978,000
Q4 2019

Jan 29, 2020

SELL
$61.62 - $67.78 $12,324 - $13,556
-200 Reduced 2.26%
8,634 $561,000
Q3 2019

Oct 28, 2019

SELL
$62.51 - $69.0 $30,004 - $33,120
-480 Reduced 5.15%
8,834 $560,000
Q2 2019

Aug 01, 2019

SELL
$61.87 - $69.38 $1.73 Million - $1.94 Million
-28,026 Reduced 75.06%
9,314 $629,000
Q1 2019

May 03, 2019

SELL
$62.53 - $70.05 $6,253 - $7,005
-100 Reduced 0.27%
37,340 $2.43 Million
Q4 2018

Feb 04, 2019

SELL
$60.54 - $79.0 $333,878 - $435,685
-5,515 Reduced 12.84%
37,440 $2.34 Million
Q3 2018

Nov 08, 2018

BUY
$71.28 - $78.92 $335,372 - $371,318
4,705 Added 12.3%
42,955 $3.32 Million
Q2 2018

Aug 13, 2018

SELL
$64.88 - $75.68 $2.79 Million - $3.25 Million
-42,990 Reduced 52.92%
38,250 $2.71 Million
Q1 2018

May 01, 2018

SELL
$72.84 - $88.8 $1.2 Million - $1.46 Million
-16,480 Reduced 16.86%
81,240 $6.13 Million
Q4 2017

Jan 29, 2018

BUY
$71.15 - $83.52 $63,323 - $74,332
890 Added 0.92%
97,720 $7 Million
Q3 2017

Nov 09, 2017

BUY
$72.11 - $85.47 $1.76 Million - $2.09 Million
24,470 Added 33.82%
96,830 $7.85 Million
Q2 2017

Aug 07, 2017

BUY
N/A
72,360
72,360 $5.12 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Twin Capital Management Inc Portfolio

Follow Twin Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twin Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Twin Capital Management Inc with notifications on news.